Fig 1: Cell characterization and purification. Phase-contrast micrographs of live primary cultured N-Fbs (A), cardiac fibroblasts (B), Schwann cells (C). Scale bar, 100 µm. Immunofluorescence for fibroblast marker CD90 in purified N-Fbs (D), C-Fbs (E), and SC marker GFAP in purified SCs (F). Scale bar: (D,E) 75 µm; (F) 100 µm. Representative figures of flow cytometry analysis of purified N-Fbs (G), C-Fbs (H), SCs (I). The upper graphics are control groups, and the lower graphics are experimental groups. M1/M2 stood for the area under the curve in upper/lower graphics; the percentage of M2 relative to M1 + M2 was the percentage of IgG 488-positive cells. (J) The purity of N-Fbs, C-Fbs, and SCs (three independent experiments).
Fig 2: Immunofluorescence staining of the region of CA1 in the hippocampus on the day after experimental laparotomy. (A) GFAP immunoreactivity in the CA1 region for 18-month-old mice. (B) GFAP immunoreactivity for 15-month-old mice. (C) Mean fluorescence intensity in the region of CA1 in the hippocampus for 18-month-old mice (unpaired Student’s t-test, P<0.0001**** for No Surgery/sleep fragmentation (SF) vs. Surgery,). (D) Mean fluorescence intensity in the region of CA1 in the hippocampus for 15-month-old mice (unpaired Student’s t-test, P<0.0001**** for No Surgery/SF vs. Surgery-SF,). DAPI, nuclear marker (blue fluorescence); GFAP, astrocyte marker (green fluorescence). Scale bar: 100 µm. All data are presented as the mean ± SEM for each group (n=6 per group, 4 views each).
Supplier Page from Abcam for Anti-GFAP antibody